Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NY-ESO-1 Positive Clear all
Active, not recruiting Phase 2 Interventional Results available

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05993299
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
10 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

NCT03709706
View directory record Official record
Conditions
Neoplasms
Interventions
Lete-cel, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Early Phase 1 Interventional Results available

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

NCT02774291
View directory record Official record
Conditions
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 66 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02588612
View directory record Official record
Conditions
Neoplasms
Interventions
letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT06703346
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

NCT03515551
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
IMCnyeso
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Iowa City, Iowa • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Results available

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05943990
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3845097, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn Phase 1 Interventional

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

NCT03506802
View directory record Official record
Conditions
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
18F-FHBG, Aldesleukin, Cellular Therapy, Computed Tomography, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, Leukapheresis, Melphalan, Plerixafor, Positron Emission Tomography
Radiation · Biological · Procedure + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Results available

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

NCT04526509
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3901961, GSK3845097, GSK4427296, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Jacksonville, Florida • Atlanta, Georgia • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

NCT05989828
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Ultrasound Imaging
Biological · Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

NCT03168438
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel, Letetresgene autoleucel with pembrolizumab, Fludarabine, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

NCT02992743
View directory record Official record
Conditions
Neoplasms
Interventions
letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861
View directory record Official record
Conditions
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
Interventions
18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography, Filgrastim, Fludarabine, Leukapheresis, Plerixafor, Positron Emission Tomography
Other · Biological · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

NCT03967223
View directory record Official record
Conditions
Neoplasms
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Drug
Lead sponsor
USWM CT, LLC
Industry
Eligibility
10 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

NCT03450122
View directory record Official record
Conditions
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
Interventions
Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Dendritic Cell-targeting Lentiviral Vector ID-LV305
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 21, 2026, 2:19 PM EDT